Solaris Resources Inc. (CVE:SLS – Free Report) – Investment analysts at HC Wainwright dropped their FY2024 EPS estimates for Solaris Resources in a research note issued to investors on Monday, November 18th. HC Wainwright analyst H. Ihle now expects that the company will post earnings per share of ($0.56) for the year, down from their previous estimate of ($0.45). HC Wainwright currently has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Solaris Resources’ FY2025 earnings at ($0.44) EPS.
Solaris Resources Stock Down 2.7 %
CVE:SLS opened at C$6.15 on Wednesday. The business’s 50-day simple moving average is C$6.15. Solaris Resources has a 1 year low of C$1.38 and a 1 year high of C$7.09.
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Articles
- Five stocks we like better than Solaris Resources
- How to Use the MarketBeat Dividend Calculator
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Manufacturing Stocks Investing
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- How to Use the MarketBeat Stock Screener
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
